Abstract
Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene that codifies the protein huntingtin and characterized by neurodegeneration of certain areas of the brain, particularly the striatum and the cortex. The first symptoms usually appear in mid-life and include cognitive deficits and motor disturbances that progress over time. The disease is invariable fatal and there is currently no cure for individuals affected with this disorder. In a search to find a cure for this devastating neurodegenerative disorder, numerous pharmacological compounds have now been tested through preclinical trials that have heavily relied on the various transgenic mouse models that are currently available to study HD. Unfortunately however, to date the benefits observed in the clinical setting have been somewhat limited. We have recently published a review article comparing the results of these preclinical studies with the outcomes of the corresponding clinical trials involving HD afflicted individuals (Brocardo and Gil- Mohapel, 2012, Current Psychopharmacology 1:137-154). In the present article we present an update to our previous review, where the new preclinical and clinical studies that have been performed over the past year have been also discussed with the goal of further elucidating the efficacy of the pharmacological treatments that have been attempted in both transgenic HD mouse models and human HD patients. By providing and maintaining an up-to-date overview of the most current literature, we hope that patterns will emerge that will guide the design of more effective preclinical and clinical studies, such as the use of combination therapies that utilize different cocktails of pharmacological compounds to simultaneously target different intracellular pathways that are affected in HD.
Keywords: Behavioural deficits, clinical trial, Huntington’s disease, neuropathology, preclinical study, transgenic model, therapeutic strategy.
Current Psychopharmacology
Title:From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease
Volume: 2
Author(s): Patricia S. Brocardo and Joana M. Gil-Mohapel
Affiliation:
Keywords: Behavioural deficits, clinical trial, Huntington’s disease, neuropathology, preclinical study, transgenic model, therapeutic strategy.
Abstract: Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene that codifies the protein huntingtin and characterized by neurodegeneration of certain areas of the brain, particularly the striatum and the cortex. The first symptoms usually appear in mid-life and include cognitive deficits and motor disturbances that progress over time. The disease is invariable fatal and there is currently no cure for individuals affected with this disorder. In a search to find a cure for this devastating neurodegenerative disorder, numerous pharmacological compounds have now been tested through preclinical trials that have heavily relied on the various transgenic mouse models that are currently available to study HD. Unfortunately however, to date the benefits observed in the clinical setting have been somewhat limited. We have recently published a review article comparing the results of these preclinical studies with the outcomes of the corresponding clinical trials involving HD afflicted individuals (Brocardo and Gil- Mohapel, 2012, Current Psychopharmacology 1:137-154). In the present article we present an update to our previous review, where the new preclinical and clinical studies that have been performed over the past year have been also discussed with the goal of further elucidating the efficacy of the pharmacological treatments that have been attempted in both transgenic HD mouse models and human HD patients. By providing and maintaining an up-to-date overview of the most current literature, we hope that patterns will emerge that will guide the design of more effective preclinical and clinical studies, such as the use of combination therapies that utilize different cocktails of pharmacological compounds to simultaneously target different intracellular pathways that are affected in HD.
Export Options
About this article
Cite this article as:
Brocardo S. Patricia and Gil-Mohapel M. Joana, From Preclinical to Clinical Trials: An Update on Potential Therapies for Huntington’s Disease, Current Psychopharmacology 2013; 2 (2) . https://dx.doi.org/10.2174/2211556011302020003
DOI https://dx.doi.org/10.2174/2211556011302020003 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
Neuromodulation for the treatment of psychiatric disorders
Neuromodulation techniques, including transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), magnetic seizure therapy (MST), electroconvulsive therapy (ECT), theta burst stimulation (TBS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), have been widely employed in the therapeutic management of prevalent psychiatric conditions such ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued) Predictive Value of Sirtuins in Acute Myocardial Infarction - Bridging the Bench to the Clinical Practice
Current Pharmaceutical Design EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Editorial: [Hot Topic: Recent Developments in Biomarker Patenting for AKI]
Recent Patents on Biomarkers Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Network Pharmacology, Molecular Docking Analysis and Molecular Dynamics Simulation of <i>Scutellaria baicalensis</i> in the Treatment of Liver Fibrosis
Current Pharmaceutical Design Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets FK506 and Its Analogs - Therapeutic Potential for Neurological Disorders
Current Drug Targets - CNS & Neurological Disorders Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Heat Shock Proteins in Diabetes and Wound Healing
Current Protein & Peptide Science FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Current Drug Delivery